WO2012075602A1 - 超声微泡靶向定位控释药物/基因装置及靶向转移的方法 - Google Patents
超声微泡靶向定位控释药物/基因装置及靶向转移的方法 Download PDFInfo
- Publication number
- WO2012075602A1 WO2012075602A1 PCT/CN2010/001987 CN2010001987W WO2012075602A1 WO 2012075602 A1 WO2012075602 A1 WO 2012075602A1 CN 2010001987 W CN2010001987 W CN 2010001987W WO 2012075602 A1 WO2012075602 A1 WO 2012075602A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- gene
- ultrasonic
- microbubble
- contrast agent
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 130
- 239000003814 drug Substances 0.000 title claims abstract description 124
- 229940079593 drug Drugs 0.000 title claims abstract description 124
- 238000012546 transfer Methods 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 22
- 239000002872 contrast media Substances 0.000 claims abstract description 78
- 238000012544 monitoring process Methods 0.000 claims abstract description 60
- 230000033001 locomotion Effects 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims description 54
- 238000002604 ultrasonography Methods 0.000 claims description 49
- 238000013270 controlled release Methods 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 23
- 230000006378 damage Effects 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 11
- 230000009471 action Effects 0.000 claims description 10
- 230000005540 biological transmission Effects 0.000 claims description 10
- 230000004807 localization Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 238000011156 evaluation Methods 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 5
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 5
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 5
- 239000004005 microsphere Substances 0.000 claims description 5
- 229940044683 chemotherapy drug Drugs 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 239000005090 green fluorescent protein Substances 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 2
- 230000018109 developmental process Effects 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000004043 dyeing Methods 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 23
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 238000002583 angiography Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 102000058223 human VEGFA Human genes 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 241001659321 ANME-2 cluster Species 0.000 description 1
- 108010056388 Albunex Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010008908 FS 069 Proteins 0.000 description 1
- 241001180649 Myrcia group Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960005423 diatrizoate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the invention belongs to the field of biomedical engineering technology, and particularly relates to an ultrasonic microbubble targeted localization controlled release drug/gene device and a method for realizing targeted transfer by using a microbubble contrast agent and a drug/gene combined with ultrasonic waves. Background technique
- Drug/gene transfer is a key technology that leverages the biological effects of the drug/gene itself.
- Current pharmaceutical/gene delivery vectors are commonly found in viruses and non-virals, such as direct injection of drugs/genes, cytoplasmic mediation, receptor-mediated, particle bombardment, electroporation, and the like.
- microbubble contrast agent combines specific drugs/genes with microbubble contrast agents, and through peripheral vascular injection, ultrasonically destroys microbubbles carrying genes, making microbubbles in specific tissues. Positioning release, this new drug/gene transfer method has the advantages of non-invasive, efficient, easy to operate, good targeting, safe and reproducible, but it is still lacking for ultrasound. A dedicated device for targeted localization of controlled release drugs/genes, especially for devices that integrate positioning, monitoring, diagnosis and treatment. Summary of the invention
- the technical problem to be solved by the present invention is to provide an ultrasonic microbubble targeted localization controlled release drug/gene device capable of improving drug/gene transmission efficiency and positioning and monitoring the same.
- Another technical problem to be solved by the present invention is to provide a method for achieving targeted transfer using a microbubble contrast agent in combination with a drug/gene.
- the technical solution adopted to solve the technical problem of the present invention is the ultrasonic microbubble targeted positioning controlled release drug/gene device, including an ultrasonic trigger/treatment unit, a driving unit, the device further comprising a monitoring unit, a motion system and a computer control unit, and the ultrasound
- the triggering/treatment unit and the monitoring unit are connected to the motion system
- the driving unit is connected to the ultrasound trigger/therapy unit
- the computer control unit is respectively connected to the motion system, the driving unit and the monitoring unit.
- the computer control unit includes an input system, a calculation center, and an output system
- the input system includes input devices such as a keyboard, information of the monitoring unit, information of the motion system, information of the driving unit, and the like.
- the computing center consists of hardware and software.
- the hardware includes one or more information acquisition card/circuit interfaces, a central processing unit, one or more output circuit interfaces, and an information display device such as a sound/image.
- the software includes system software, data/image processing software, and application software that is easy to operate/display, wherein the system software and the data/image processing software constitute an application.
- the operating software sets parameters, and the information is transmitted to the motion system and the driving unit through the output circuit interface.
- the driving unit drives the triggering/treatment unit to transmit ultrasonic energy, the monitoring unit monitors the treatment situation, and feeds the information back to the information acquisition card through data/image processing.
- the application automatically performs the corresponding processing or prompts the operator to perform corresponding operations, identify the organizational features, and display them by numbers, colors, texts, and the like.
- the ultrasonic monitoring unit is preferably a B-ultrasound.
- the software further includes an application coupled to the central processor and the output circuit outlet, respectively.
- the application includes data/image processing software and application software.
- the application also includes data/image processing software and application software coupled to the display device for assessing drug/gene targeted transmission effects.
- the application controls the ultrasound trigger/treatment unit to act on the tissue by calculating the power and the action time, and displays the image information (number, color, text, etc.) at the appropriate time before and after the action through the display device, and changes the situation according to the image information. Judging whether the satisfactory effect is achieved. If it is considered that the satisfactory effect is not achieved, the appropriate power and time are adjusted by the application software to continue to act on the target organization to guide the satisfactory results.
- the device may also include a cooling unit coupled to the ultrasound trigger/therapy unit.
- the ultrasonic monitoring unit and the ultrasonic trigger/treatment unit are fixed together, and there are various methods of fixing.
- the middle portion of the ultrasonic trigger/treatment unit has a hole through which the monitoring probe of the monitoring unit passes. Attached to the ultrasound trigger/treatment head in the ultrasound trigger/treatment unit.
- the monitoring unit and the ultrasonic trigger/treatment unit are fixed together, and in the monitoring image, the position of the action area of the ultrasonic trigger/treatment unit can be accurately indicated, and the image change of the active area can be accurately observed during use, and Timely evaluation of results.
- the device of the invention can use ultrasonic to trigger the destruction of microbubble real drug/gene targeted transmission, and can evaluate the effect of drug/gene targeted transfer, integrate diagnosis, treatment and evaluation, and use healthy New Zealand white rabbit as experimental object. Prove that the device of the invention can significantly improve drug/gene transmission Efficiency
- the ultrasonic trigger/therapy unit is driven by the driving unit to emit ultrasonic waves to destroy the microbubbles;
- step (5) further comprises the following drug/gene transfer effect evaluation steps:
- the computer control unit collects real-time image information (number, color, text, etc.) of the target tissue monitored by the ultrasonic monitoring unit through the image acquisition card;
- the drive unit drives the ultrasonic trigger/treatment unit to emit ultrasonic waves to destroy the microbubbles
- the corresponding parameters are set by the application software, and then the ultrasonic waves are emitted.
- the range of ultrasonic waves emitted by the ultrasonic trigger/treatment unit is
- the sound intensity range is 0. 25 ⁇ 3 W / cm 2 , preferably 0. 5W / cm 2
- the action time is 0. 25 ⁇ 3 minutes, preferably 1 minute.
- step (1) the microbubble contrast agent is combined with the drug/gene to form a drug/gene-containing microbubble contrast agent which adheres the drug/gene to the surface of the microbubble contrast agent, ie, the selected drug/gene and lipid
- the microbubble contrast agent is mixed in a ratio of (3 to 10):10 by volume, and the drug/gene is adhered to the surface of the microbubble by electrostatic adsorption. That is, the drug/gene-loaded microbubble contrast agent is obtained by adhering a commercially available contrast agent or a self-contained contrast agent to a surface of a microbubble contrast agent, and the purchased microbubble contrast agent and drug/gene are obtained.
- Combining the formation of drug/gene-containing microbubble contrast agent is to adhere the drug/gene to the microbubble contrast agent by volume (3 ⁇ 10): 10, and adhere the drug/gene to the microbubble by electrostatic adsorption. surface.
- step (1) is carried out with a drug/gene microbubble contrast agent.
- Another method of making a self-contained contrast agent is to use a self-made contrast agent to produce a drug/gene microbubble contrast agent by: drug/gene wrapping In the microbubbles, the fluorocarbon gas which is liquid at a low temperature is mixed with the drug/gene by volume (3 ⁇ 5): 1, and the fluorocarbon liquid and the drug/gene are encapsulated by the lipid material under ultrasonic vibration.
- microspheres become microbubbles at a temperature rise of 37 °C to 45 °C, and the unencapsulated drug/gene is washed with a buffer (such as PBS buffer), and the resulting package is a package.
- a buffer such as PBS buffer
- the microbubble contrast agent and the drug/gene adhesion form a drug/ a microbubble contrast agent of a gene, which is attached to a corresponding antibody of a specific tissue antigen or a ligand for a specific receptor on a surface of a microbubble, and various antibodies are mixed into a liquid during an acoustic vibration process to form a targeted ultrasound.
- Microbubble contrast agent is attached to a corresponding antibody of a specific tissue antigen or a ligand for a specific receptor on a surface of a microbubble, and various antibodies are mixed into a liquid during an acoustic vibration process to form a targeted ultrasound.
- the above-mentioned drugs are tumor chemotherapy drugs, antibiotics or various protein and polypeptide drugs, and the genes are vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), etc. , marker genes such as: green fluorescent protein gene (GFP), ⁇ -galactosidase gene.
- VEGF vascular endothelial growth factor
- HGF hepatocyte growth factor
- FGF fibroblast growth factor
- marker genes such as: green fluorescent protein gene (GFP), ⁇ -galactosidase gene.
- the method of the invention is non-invasive, simple and reusable.
- FIG. 1 is a structural block diagram of an ultrasonic microbubble targeted localization controlled release drug/gene and effect evaluation device according to the present invention
- FIG. 2 is a perspective view showing the structure of the ultrasonic monitoring unit 3 and the ultrasonic trigger/treatment unit 2 of the present invention (when the outer casing is horizontally placed)
- Figure 3 is a perspective view showing the structure of the ultrasonic monitoring unit 3 and the ultrasonic trigger/treatment unit 2 of the present invention (when the outer casing is placed upright)
- FIG. 4 is a structural block diagram of the computer control unit 4 of the present invention -
- FIG. 5A is a digital subtraction angiography diagram of the control group of the ultrasound microbubble carrying gene for promoting regeneration of the present invention.
- Figure 5 ⁇ is a digital subtraction angiography of the experimental group of the ultrasound microbubble carrying gene angiogenesis in the present invention.
- the ultrasonic microbubble targeted positioning controlled release drug/gene apparatus of the present invention comprises an ultrasonic triggering/treatment unit 2, a monitoring unit 3, a driving unit 4 for driving the ultrasonic triggering/treatment unit 2 to emit ultrasonic waves, a motion system 5,
- the computer control unit 6 and the cooling unit 7 are connected to the monitoring unit 3 and the driving unit 4 and the motion system 5, respectively, and the driving unit 4 and the cooling unit 7 are connected to the ultrasound trigger/treatment unit 2, respectively.
- the ultrasound trigger/treatment unit 2 is used to trigger the destruction of the microbubbles to achieve drug/gene targeted transmission and to treat the target tissue 1, and the monitoring unit 3 is used to monitor the treatment of the target tissue 1.
- the ultrasonic trigger/treatment unit 2 includes an ultrasonic trigger/treatment head 20, and the monitoring unit 30 includes a monitoring probe 30.
- the monitoring unit 3 employs a B-ultrasound.
- the computer control unit 6 includes an input system, a computing center, and an output system.
- the information acquisition card/circuit interface 61 in the input system is coupled to the central processing unit 62 of the computing center, and the central processing unit 62 is coupled to the application program 63.
- the application is connected to the display device 67 in the output system, and is connected to the motion system 6 and the drive unit 5, and the information acquisition card/circuit 61 is connected to the monitoring unit 3.
- the application 63 further includes data/image processing software 65 and Application software 66, application 63 is connected to the motion system 5 and the drive unit 4 via an output circuit interface 68.
- a certain technical parameter can be set in the application software 66, so that the ultrasonic trigger/treatment head 20 acts on the target tissue 1 with a certain power and action time, and the image information collected by the information acquisition card/circuit interface 61 before and after the action. (Digital, image, text, etc.) is presented by the display device, and it is judged whether the satisfactory effect is achieved according to the change of the image information. If it is considered that the satisfactory effect is not achieved, the application software 63 appropriately adjusts the power and time, and continues. The target tissue 1 is allowed to act until a satisfactory effect is achieved.
- the singularity of the ultrasonic wave is a pulsed wave or a continuous wave
- the frequency may be 20 KHz ⁇ 2 ⁇ 2
- the intensity may be 0. 25- 3 W/cm
- the monitoring probe 30 of the monitoring unit 3 i.e., the B-ultrasound probe
- the ultrasonic trigger/treatment head 20 of the ultrasonic trigger/treatment unit 2 are integrated. As shown in Fig. 2 and Fig. 3, in the middle of the ultrasonic trigger/treatment head 20, there is a hole through which the monitoring probe 30 can pass, and the monitoring probe 30 is fixed in the hole.
- the outer portion of the ultrasonic trigger/treatment unit 2 is surrounded by a housing 9, and the ultrasonic trigger/treatment head 20 and the housing 9 are fixed together by a screw through the hole 11 and the lower portion of the monitoring probe 30 has a connecting tube 8, a screw.
- the outer casing 9 and the connecting tube 8 are fixed by the hole 12 so that the outer casing 9 integrally fixes the ultrasonic trigger/treatment head 20 and the monitoring probe 30.
- An aperture 13 for the cable for connecting the ultrasonic trigger/treatment head 20 to the drive unit 4 and the computer control unit 6 is provided in the housing 9, and the aperture 13 is also a cooling passage that communicates with the cooling unit 7.
- the ultrasonic trigger/treatment head 20 includes an ultrasonic transducer, and the ultrasonic transducer has a hole 10 for use as an inlet and drain passage of the ultrasonic transducer, and the ultrasonic trigger/treatment head 20
- the sound permeable membrane 14 is fixed to the end by bonding or other means.
- the monitoring probe 30 and the ultrasonic trigger/treatment head 20 move in the direction of the target tissue 1, and the ultrasonic trigger/treatment head 20 emits ultrasonic waves to trigger destruction of the microbubbles to achieve drug/gene targeted transmission and target tissue 1 treatment.
- the device of the present invention When the device of the present invention is used to implement the ultrasonic destruction microbubbles to achieve the drug/gene targeted transfer effect, it is first necessary to combine the microbubble contrast agent with the drug/gene to form a drug/gene microbubble contrast agent, which is injected through the peripheral blood vessel. Carrying the drug/gene microbubble contrast agent, and then using the ultrasonic sonogram generated in the monitoring unit 3 to monitor the targeted transfer of the drug/gene microbubble contrast agent and the ultrasonic destruction of the drug/gene microbubble to make the microbubble
- the specific method of positioning release in a specific organization is as follows:
- Adhering the drug/gene to the surface of the microbubble contrast agent Mixing the selected drug/gene with the lipid microbubble contrast agent by volume in a ratio of (3 to: 10): 10 (ie: making the mixture The amount of the drug/gene is about 0.1 to 1 mg /ml), and the drug/gene is adhered to the surface of the microbubble by electrostatic adsorption to prepare a microbubble contrast agent for adhering the drug/gene to the surface;
- the driving unit 4 drives the ultrasonic trigger/treatment head 20 of the ultrasonic trigger/treatment unit 2 to emit ultrasonic damage microbubbles, micro
- the "cavitation effect” and “sound hole effect” after bubble destruction can cause microvascular rupture and cell membrane to produce sound holes, which can significantly increase the transfection rate of the gene in target tissue 1.
- Steps of evaluating the effect after drug/gene transfer After the ultrasonic damages the microbubbles, the application software uses the image information collected by the information acquisition card/circuit interface 61 to arrive at the microbubble contrast agent carrying the gene displayed in the display device. The image information of the target tissue and its transfection and expression is compared. According to the change of the image information, the software 66 is appropriately adjusted to set the relevant parameters, and the target tissue 1 is continued to be operated until the purpose of directional transfer and positioning and controlled release is achieved.
- the cooling water is supplied by the cooling unit 7 to cool the heat generated by the ultrasonic trigger/treatment unit 2 throughout the operation of the present invention.
- Figures 5A and 5B show a comparatively significant angiogenic effect of the ultrasound microbubble drug/gene.
- the specific experiments are as follows: Healthy New Zealand white rabbits as experimental subjects, weighing 2.5 ⁇ 3 kg, new muscle anesthesia (0.1 ⁇ 0.15 ml/kg), depilated with 8% Na 2 S, fixed on the console on the back.
- the left lower extremity femoral artery and its branch ligation resulted in a model of lower extremity occlusive vascular disease.
- the experimental group was the ultrasound microbubble treatment group (A), the control group included the blank control group (B), the pure ultrasound irradiation group (C:), and the simple microbubble treatment group ( D).
- the microbubbles used in the experiment were albumin microbubble contrast agents with a contrast agent concentration of 8.3 X 108 cells/ml and a microbubble size of 2.7 ⁇ 0.8 m.
- Group A was successfully injected with localized albumin microbubbles and The mixture pcDNA3.1 / VEGF165 plasmid containing pcDNA3.1 / VEGF165 plasmid 25 ⁇ ⁇ , and irradiation with ultrasonic waves, the parameters transmission frequency 1 MHz, the sound intensity of 2.0 W / cm 2, irradiating l min; group B No ultrasound and microbubble treatment were used, which was a blank control group.
- group C ultrasound irradiation was used only under the premise of microbubbles, and the parameters were the same as those in group A.
- Group D was treated with microbubbles alone. After successful modeling, the skeletal muscle was used to input pcDNA3.1/VEGF165 plasmid 25 ⁇ ⁇ , not used Ultrasonic irradiation. Intra-abdominal intubation was performed 4 weeks after surgery, and 2 mL of 76% diatrizoate contrast agent was injected within 1 s. The results of angiography were recorded by continuous film photography. The photographic speed was 25 ⁇ /s, and the circulation of new blood vessels and collaterals was observed.
- the formation status showed that the number of skeletal muscle neovascularization in the control group was small (as shown in Fig. 5A), while the number of skeletal muscle neovascularization in the experimental group, that is, the ultrasonic microbubble treatment group was significantly increased (as shown in Fig. 5B). It indicated that ultrasound destruction of VEGF165 gene microbubbles can significantly promote angiogenesis of ischemic skeletal muscle.
- the microbubble contrast agent can be a self-contained contrast agent, or a directly purchased microbubble contrast agent such as Sonovue produced in Italy, Optison, Albunex produced in the United States, Levovist produced in Germany, or a self-made acoustic contrast agent.
- the commercially available microbubble contrast agent or self-contained contrast agent can be used to adhere to the drug/gene, and the corresponding antibody against a specific tissue antigen or a ligand for a specific receptor can be attached to the surface of the microbubble, and the microbubble can be greatly improved. Targeting role.
- anti-CD34, anti-ICAM, anti-E-selectin, anti-P-selectin, etc. various antibodies are mixed into the liquid during the acoustic vibration process to form a targeted ultrasonic microbubble contrast agent.
- the gene involved in the method of the present invention is an available existing gene, and various growth factors such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), etc.; : Green fluorescent protein gene (GFP), ⁇ -galactosidase gene, and the like.
- VEGF vascular endothelial growth factor
- HGF hepatocyte growth factor
- FGF fibroblast growth factor
- Drugs suitable for this embodiment include all biologically active substances such as tumor chemotherapy drugs, antibiotics, and various proteins, polypeptide drugs, and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Acoustics & Sound (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgical Instruments (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2010/001987 WO2012075602A1 (zh) | 2010-12-08 | 2010-12-08 | 超声微泡靶向定位控释药物/基因装置及靶向转移的方法 |
AU2010365282A AU2010365282B2 (en) | 2010-12-08 | 2010-12-08 | Ultrasonic microbubble target-locating controlled releasing drug/gene device and target transfer method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2010/001987 WO2012075602A1 (zh) | 2010-12-08 | 2010-12-08 | 超声微泡靶向定位控释药物/基因装置及靶向转移的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012075602A1 true WO2012075602A1 (zh) | 2012-06-14 |
Family
ID=46206507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/001987 WO2012075602A1 (zh) | 2010-12-08 | 2010-12-08 | 超声微泡靶向定位控释药物/基因装置及靶向转移的方法 |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2010365282B2 (zh) |
WO (1) | WO2012075602A1 (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101028524A (zh) * | 2006-03-03 | 2007-09-05 | 重庆融海超声医学工程研究中心有限公司 | 超声微泡靶向定位控释药物/基因装置及靶向转移的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1909908B1 (en) * | 2005-06-02 | 2011-03-30 | Cancercure Technology AS | Ultrasound treatment system |
-
2010
- 2010-12-08 AU AU2010365282A patent/AU2010365282B2/en active Active
- 2010-12-08 WO PCT/CN2010/001987 patent/WO2012075602A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101028524A (zh) * | 2006-03-03 | 2007-09-05 | 重庆融海超声医学工程研究中心有限公司 | 超声微泡靶向定位控释药物/基因装置及靶向转移的方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2010365282B2 (en) | 2014-02-27 |
AU2010365282A1 (en) | 2012-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Deprez et al. | Opening doors with ultrasound and microbubbles: Beating biological barriers to promote drug delivery | |
JP5689416B2 (ja) | 超音波仲介による薬送達 | |
Wang et al. | Ultrasound and microbubble guided drug delivery: mechanistic understanding and clinical implications | |
Li et al. | Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice—initial results | |
Hynynen | Ultrasound for drug and gene delivery to the brain | |
Hauff et al. | Evaluation of gas-filled microparticles and sonoporation as gene delivery system: feasibility study in rodent tumor models | |
Kinoshita et al. | A novel method for the intracellular delivery of siRNA using microbubble-enhanced focused ultrasound | |
US8012092B2 (en) | Method of using a combination imaging and therapy transducer to dissolve blood clots | |
CN101028524B (zh) | 超声微泡靶向定位控释药物/基因装置及靶向转移的方法 | |
JP4807778B2 (ja) | 超音波薬剤装置及び医用画像診断装置 | |
Udroiu | Ultrasonic drug delivery in Oncology | |
CN102233159A (zh) | 聚焦超声无创伤声动力肿瘤治疗系统 | |
Deng et al. | Improving the efficacy of therapeutic angiogenesis by UTMD-mediated Ang-1 gene delivery to the infarcted myocardium | |
US20120029397A1 (en) | Tumor treatment using ultrasound cavitation | |
Ho et al. | Ultrasonic technologies in imaging and drug delivery | |
Papadopoulos et al. | In vitro evaluation of focused ultrasound-enhanced TNK-tissue plasminogen activator-mediated thrombolysis | |
Zolochevska et al. | Advances in sonoporation strategies for cancer | |
Hu et al. | Ultrasound microbubble contrast agents: application to therapy for peripheral vascular disease | |
CN101244028A (zh) | 一种药物定位递送和定量控释系统 | |
WO2012075602A1 (zh) | 超声微泡靶向定位控释药物/基因装置及靶向转移的方法 | |
Wawryka et al. | Microbubble based sonoporation—from the basics into clinical implications | |
JPH07213622A (ja) | 薬剤投与装置 | |
JP2005500327A (ja) | 肝臓へのdnaのトランスフェクションの増強 | |
Harmon et al. | Ultrasound-guided gas embolization using a single linear array transducer | |
Miao et al. | Ultrasound-mediated gene delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10860428 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2010365282 Country of ref document: AU Date of ref document: 20101208 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10860428 Country of ref document: EP Kind code of ref document: A1 |